A phase 4 single-arm open-label clinical study of pembrolizumab (MK-3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Head And Neck Squamous Cell Carcinoma
-
Age: Between 18 years - 120 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Has histologically or cytologically-confirmed diagnosis of R/M HNSCC that is considered incurable by local therapies and has not had prior systemic therapy administered in the recurrent or metastatic setting. 2) Has a primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx. 3) Does NOT have a primary tumor site of nasopharynx (any histology). 4) Does NOT have an unknown primary tumor.
You may not be eligible for this study if the following are true:
-
1) Medical Conditions - Has had an allogenic tissue/solid organ transplant. 2) Has disease that is suitable for local therapy administered with curative intent. 3) Has progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC. 4) Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
